ArticleClinical rheumatology2025
Other musculoskeletal disorders in China, 1990-2021, and projections to 2050: findings from the Global Burden of Disease Study 2021.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The prevalence and influencing factors of dynapenia among middle-aged and elderly individuals with knee osteoarthritis: a cross-sectional analysis.BMC musculoskeletal disorders · 2026Article
- Non-communicable disease burden in China, 1990-2023: Evidence from the Global Burden of Disease Study 2023.Chinese medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesOther musculoskeletal disorders showed a growing burden globally, but data specific to China remain sparse. This study aims to analyze the burden of other musculoskeletal disorders in China from 1990 to 2021 using data from the Global Burden of Disease (GBD) 2021.
methodsDecomposition analysis, Bayesian Age-Period-Cohort, and Age-Period-Cohort models were utilized to investigate the key influencing factors and project future burden.
resultsIn China, the prevalence of other musculoskeletal disorders was 85.0 (72.4-99.4) million in 2021, with a 20% increase from 1990. The number of Disability-Adjusted Life Years (DALYs) was 7.6 (5.2-10.6) million in 2021, indicating a 18.1% rise. Although age-standardized mortality rate remained stable, deaths number increased from 5,279.4 (4,289.9-6,724.3) to 9,166.9 (7,000.8-11,693.4). Females consistently showed higher rates than males, while China remained below the global average in prevalence, DALYs, and mortality. Population growth was the predominant contributor to the burden's increase in China, showing a different pattern from other BRICS countries. Prevalence is projected to triple by 2050, while DALYs and mortality may decline. For Age-Period-Cohort analysis of mortality, net drift was below zero. Age effects exhibited a significant increase after age group 70-75. Period effects played a negative role after 2004-2005. Cohort effects revealed a notable decrease among more recent generation.
conclusionsThe burden of other musculoskeletal disorders in China is increasing with sex, age, and regional differences. Future growth in prevalence is predicted for this category of disorders, highlighting the need for effective public health policies and tailored interventions. Key Points • The burden of other musculoskeletal disorders in China is substantial and has been growing from 1990 to 2021, with significant sex, age, and regional differences. • Population growth is the predominant contributor to the increased burden of other musculoskeletal disorders in China, showing a distinct pattern compared to other BRICS countries.
Indexed as
Identifiers
40301188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.